Analysis of Biopsy Specimens to Study Responses to PD-1 or PD-L1 Therapies

Study summary

The purpose of this study is to attempt to obtain an on-treatment biopsy in participants with non-small cell lung cancer who are receiving standard treatment with a drug that targets the PD-1 or PD-L1 protein.

Ask AI to explain this study

Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedPre-Treatment Biopsy and On-Treatment Biopsy

Plus 2 other study approaches.

Who it may be forNon-small cell lung cancer (NSCLC) · PD-L1

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated May 15, 2025 · Source: ClinicalTrials.gov

Is enrollment open?Withdrawn

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?6 U.S. locations

Locations may change over time.

Who runs it?Memorial Sloan Kettering Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Not specified
Study type: Observational
Phase: Not applicable
Sponsor: Memorial Sloan Kettering Cancer Center
Interventions being studied: Diagnostic Test: Pre-Treatment Biopsy; Diagnostic Test: On-Treatment Biopsy; Diagnostic Test: Biopsy at Disease Progression; Diagnostic Test: Peripheral Blood-Based Studies

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Cancer type

Non-small cell lung cancer (NSCLC)→

Biomarkers

PD-L1→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Pathologically confirmed newly diagnosed or recurrent advanced Non Small Cell Lung Cancer/NSCLC that is PI-L1 high by immunohistochemistry (PD-L1 \>/= 50%)
Intended treatment with a PD-(L)1 inhibitor
Age \>/= 18 years
Karnofsky Performance Status \>/= 70% and medically fit to undergo a biopsy procedure

Reasons someone may not be able to joinExclusion criteria

Any medical condition or any sites of disease that would preclude a biopsy
Pregnant or breastfeeding women
Cognitively impairment affecting ability to understand and provide informed consent
Prior PD-(L)1 blockade treatment
Chemotherapy within 6 months prior to enrollment

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Memoral Sloan Kettering Basking Ridge (Consent and Follow up)Basking Ridge, New Jersey
Memoral Sloan Kettering Monmouth (Consent and Follow up)Middletown, New Jersey
Memorial Sloan Kettering Bergen (Consent and Follow up)Montvale, New Jersey
Memorial Sloan Kettering Cancer Center @ Suffolk (Consent Only)Commack, New York
Memoral Sloan Kettering Westchester (Consent & Follow Up)Harrison, New York
Memorial Sloan - Kettering Cancer Center (Consent and follow-up)New York, New York

Source and freshness
Processed from ClinicalTrials.gov. Last public update: May 15, 2025. Always confirm current availability with the study team.

View original record ↗